Tyrosine phosphatase Shp2 accelerated the progression of dilated cardiomyopathy via upregulating NF-κB/Src/FAK signaling induced ROS and mitophagy
Related Experiment Video
Updated: Sep 11, 2025

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
Published on: September 6, 2024
Jingxia Hao1, Hua Wang1, Bo Li1
1Hebei Provincial Key Laboratory of Pediatric Cardiovascular Disease, Hebei Children's Hospital, Shijiazhuang, 050031, Hebei, China.
Abstract:
The purpose of this study was to investigate whether tyrosine phosphatase Shp2 can promote the progression of dilated cardiomyopathy by upregulating intracellular oxidative stress and subsequently promoting mitophagy. Macrophage-specific Shp2 knockout mice were cultured and a dilated cardiomyopathy model was established. Ultrasonography, Masson staining and WGA staining were used to detect the condition of mouse hearts. Immunofluorescence, Western blot and EL were used to detect the expression of relevant proteins in mouse myocardial tissues. Transmission electron microscopy was used to examine the morphology of mouse myocardial cells and their internal mitochondria. Primary BMMs from wild-type mice and specific Shp2 knockout mice were co-cultured with normal myocardial cell. Western blot was used to detect the expression of relevant proteins in BMMs and myocardial cells. Transwell assay was used to measure the migration and invasion ability of BMMs, and immunofluorescence staining was used to detect the expression level of PINK protein in myocardial cells to validate the Western blot results. Dilated cardiomyopathy was ameliorated in DCM mice with specific knockout of Shp2, which showed attenuation of heart structure, degree of fibrosis in myocardial tissue, and degree of cardiomyocyte dilatation. And the degree of autophagy in myocardial tissue was significantly reduced as observed by western blot and transmission electron microscopy. Subsequent cellular experiments also verified that specific knockdown of Shp2 inhibited the invasion of BMMs. And it also mediated the ROS/NF-κB/Src/FAK signalling pathway to inhibit the expression of related autophagy and apoptosis proteins. Tyrosine phosphatase Shp2 accelerated the progression of dilated cardiomyopathy via upregulating NF-κB/Src/FAK signaling induced ROS and mitophagy.
Insights
Tyrosine phosphatase Shp2 accelerates dilated cardiomyopathy by increasing oxidative stress and mitophagy. Knocking out Shp2 in macrophages improved heart structure and reduced fibrosis and cell damage in a mouse model.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Cellular Pathology
Background:
- Dilated cardiomyopathy (DCM) is a progressive heart disease.
- The role of tyrosine phosphatase Shp2 in DCM pathogenesis is not fully understood.
- Oxidative stress and mitophagy are implicated in cardiac dysfunction.
Purpose of the Study:
- To investigate if Shp2 promotes DCM progression by upregulating oxidative stress and mitophagy.
- To elucidate the molecular mechanisms linking Shp2 to DCM.
Main Methods:
- Established a dilated cardiomyopathy model in macrophage-specific Shp2 knockout mice.
- Utilized echocardiography, histology (Masson, WGA), immunofluorescence, Western blot, and transmission electron microscopy.
- Performed co-culture assays with primary bone marrow-derived macrophages (BMMs) and myocardial cells, and Transwell migration assays.
Main Results:
- Macrophage-specific Shp2 knockout ameliorated DCM, improving heart structure, reducing fibrosis, and cardiomyocyte dilatation.
- Shp2 knockout significantly decreased autophagy in myocardial tissue.
- Knockdown of Shp2 inhibited BMM invasion and modulated the ROS/NF-κB/Src/FAK signaling pathway, reducing autophagy and apoptosis proteins.
Conclusions:
- Tyrosine phosphatase Shp2 accelerates DCM progression.
- Shp2 promotes DCM by upregulating ROS and mitophagy via the NF-κB/Src/FAK signaling pathway.
- Targeting Shp2 may offer a therapeutic strategy for dilated cardiomyopathy.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
The JAK-STAT Signaling Pathway
Cardiomyopathy V: Interprofessional Care
Heart Failure II: Pathophysiology
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Cardiomyopathy II: Dilated Cardiomyopathy

